

UPDATES FROM THE



**Sentinel
Project**
on pediatric drug-
resistant tuberculosis

Soumya Swaminathan

National Institute for Research in Tuberculosis of India



**Sentinel
Project**
on pediatric drug-
resistant tuberculosis

... is a network of researchers, caregivers, and advocates who share a vision of a world where no child dies of this preventable and curable disease. We collaborate to raise the visibility of this vulnerable population, and to share evidence and resources that can increase children's access to prompt and effective treatment.



Sentinel Project = >300 members in >60 countries

Management of Multidrug-Resistant Tuberculosis in Children: A Field Guide



Second Edition: July, 2014

Sentinel Project Trainings



Workshops

- Chennai 17-19 June 2013
- Dhaka 15-17 July, 2013
- Paris 31 October 2013
- Georgia 3 July 2014
- Dushanbe 4-8 August 2014
- China 13-17 October 2014

Webinars

Date	Topic
14 Mar 2014	Demonstration of gastric aspiration technique
25 Apr 2014	Regimen design and dosing: a case-based discussion
21 May 2014	Household considerations: contact tracing and infection control
6 Jun 2014	Adverse events and adherence
23 Jul 2014	Paediatric DR-TB meningitis: a case-based discussion
19 Sep 2014	Raising voices: advocacy issues
9 Oct 2014	What's in a number? Two reports estimating childhood TB cases

Case registry for childhood DR-TB

- Under development, core data set defined
- Designed to capture information on how children with DR-TB are being diagnosed and treated
 - Diagnostic criteria
 - Baseline clinical and laboratory data
 - Treatment regimens, including regimen changes
 - Adverse events
 - Early treatment response
 - Final treatment outcome
- Electronic interface, freely available
 - Can be used to generate local reports

Date started:

30 Sept 2014

Height:

Weight:

Reason for regimen change (*check all that apply*):

- Adjusting dose for weight
 New drug susceptibility test results
 Adverse reaction to drug

Other:

Drug

Dose

Route

Frequency

- | | | | | |
|----|--------------|---------|-----------|-------------|
| 1. | Pyrazinamide | 400 mg | Oral | Once daily |
| 2. | PAS | 2000 mg | Oral | Twice daily |
| 3. | Ethionamide | 250 mg | Oral | Once daily |
| 4. | Ofloxacin | 200 mg | Oral | Once daily |
| 5. | Streptomycin | 400 mg | Injection | Once daily |

Edit

Stop

Edit

Stop

Edit

Stop

Edit

Stop

Edit

Stop

Add new drug

Steroids prescribed?

Yes

No

Unknown

Example of a
data entry form

REPORT PERIOD: 1 JAN 2015 – 31 DEC 2015

TOTAL PATIENTS ON TREATMENT DURING REPORT PERIOD: 128

TREATMENT STATUS

Started on treatment during report period:	36
Continued treatment through report period:	35
Stopped treatment during report period:	57
Treatment completed:	39 (68%)
Treatment interrupted:	12 (21%)
Patient died during treatment:	6 (11%)

DRUG SUSCEPTIBILITY TESTING

Patients with positive culture :	72
Patients with DST:	70
Monoresistant:	19 (27%)
Polyresistant:	10 (14%)
MDR:	36 (51%)
XDR:	5 (7%)

TREATMENT RESPONSE

	Report submitted	Clinical improvement	Radiological improvement	Microbiological improvement	Treatment failure
By 2 months of treatment	125	21 (17%)	18 (14%)	N/A	N/A
By 6 months of treatment	106	72 (68%)	67 (63%)	N/A	N/A
By 12 months of treatment	77	70 (91%)	68 (88%)	60 (78%)	4 (5%)
By 24 months of treatment	39	37 (95%)	37 (95%)	32 (82%)	2 (5%)

PATIENT CHARACTERISTICS

Female: 72 (56%)

HIV-positive:

Example of a possible report

Research Priorities in Childhood DRTB: Survey of Expert Stakeholders

(manuscript submitted for publication)

- 104 respondents in the online survey during July – Sep 2013.
- The top-ranked research question was to identify the best combination of existing diagnostic tools for early diagnosis of drug-resistant TB in children.
- Treatment-related questions: reasons for poor treatment outcomes, adverse effects of anti-TB drugs, optimal treatment duration and interventions for improving treatment outcomes.
- The prevalence of drug-resistant TB was the highest-ranked question in the Epidemiology area.
- The development type questions ranked highest focused on interventions for optimal diagnosis, treatment and modalities for treatment delivery.
- The predominant discovery type questions focused on new drug evaluation and models for preventive therapy and for preventing new infections.

UPDATES FROM THE



**Sentinel
Project**
on pediatric drug-
resistant tuberculosis

**Networking reception on 28th October 6:30pm
sponsored by the**

**Department of Global Health and Social Medicine
at Harvard Medical School**

and the

National Institute for Research in Tuberculosis of India

with support from

janssen 

য শূন্য eber sifir শূন্য eber sifir শূন্য eber sifir শূন্য eber sifir শূন্য eber sifir শূন্য eber sifir শূন্য
A zero 零 IQUANDA zero 零 IQUANDA zero 零 IQUANDA zero 零 IQUANDA zero 零 IQUANDA zero

শূন্য ноль cero ॐ শূন্য ноль cero ॐ শূন্য ноль cero ॐ শূন্য ноль cero ॐ শূন্য H
sifuri صفر null ॐ sifuri صفر null ॐ sifuri صفر null ॐ sifuri صفر null ॐ sifuri صفر null ॐ sifuri